These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24913471)

  • 21. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
    Bradley AM; Devine M; DeRemer D
    Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
    Beaven AW; Diehl LF
    Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
    Foyil KV; Kennedy DA; Grove LE; Bartlett NL; Cashen AF
    Leuk Lymphoma; 2012 Mar; 53(3):506-7. PubMed ID: 21867368
    [No Abstract]   [Full Text] [Related]  

  • 24. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
    Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
    Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
    Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
    Garnock-Jones KP
    Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature.
    Chernova NG; Zvonkov EE; Badmazhapova DS; Sinitsyna MN; Grebenyuk LA; Sidorova YV; Kostina IE; Kovrigina AM; Obukhova TN; Sudarikov AB; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):77-81. PubMed ID: 30701926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.
    Broccoli A; Derenzini E; Pellegrini C; Narducci R; Stefani G; Casadei B; Argnani L; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):493-5. PubMed ID: 23726017
    [No Abstract]   [Full Text] [Related]  

  • 33. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
    Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.
    DeVita MD; Evens AM; Rosen ST; Greenberger PA; Petrich AM
    J Natl Compr Canc Netw; 2014 Apr; 12(4):465-71. PubMed ID: 24717566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
    Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
    Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin.
    Ansell SM
    Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
    Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
    Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
    [No Abstract]   [Full Text] [Related]  

  • 39. Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.
    Onaka T; Kitagawa T; Kawakami C; Yonezawa A
    Turk J Haematol; 2018 May; 35(2):135-136. PubMed ID: 29391331
    [No Abstract]   [Full Text] [Related]  

  • 40. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
    Calleja A; Bouclet F
    Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.